Skip to content
Home/Companies/Biotech/Kamau Therapeutics
Kamau Therapeutics

Kamau Therapeutics

Biotech·US·Active·2yr hold
Entry
2024
Hold
2yr
Status
Active

Who owns Kamau Therapeutics?

Kamau Therapeutics is currently owned by Neva SGR through Neva II (2024 vintage), since 2024.

Hand-verified · updated 2026-07-23

Neva SGR
Investor
Neva SGR
Neva II · 2024 · VC

Key facts

HQUnited States
SectorBiotech
StatusActive
Websitekamautx.com

More from Neva II

Other portfolio companies in the same fund.

Straiker
Straiker
Active
CybersecurityUS· 2026
Commonwealth Fusion Systems
Active
ClimateTechUS· 2025
deskbird
deskbird
Active
HR TechSwitzerland· 2025
Nuclidium
Active
BiotechSwitzerland· 2025
Phosphorus
Phosphorus
Exited 2026
CybersecurityUS· 2025
to
Ternary
Ternary
Active
SaaSUS· 2022

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS
Track Kamau Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Who could buy Kamau Therapeutics?

7 strategic and 113financial buyers match this company's sector and geography profile, ranked from verified European deal history.

Find likely buyers

Get the full record on Kamau Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue